Cookie policy notice

By continuing to use this site you agree to our cookies policy below:
Since 26 May 2011, the law now states that cookies on websites can ony be used with your specific consent. Cookies allow us to ensure that you enjoy the best browsing experience.

This site is intended for health professionals only

At the heart of general practice since 1960

Pneumococcal jab in elderly queried

A new vaccine against streptococcal A infection is well tolerated and capable of stimulating an immune response, according to an early trial.

Work on streptococcal A vaccines was halted in the 1970s because of safety fears but is now a priority after increasing problems with antibiotic resistance.

In the new phase I trial, published in JAMA (August 11), healthy volunteers were given a vaccine made from several proteins from the streptococcus A bacterium. They produced immune responses that are likely to confer protection against a range of subtypes of streptococcal A infection.

Rate this article 

Click to rate

  • 1 star out of 5
  • 2 stars out of 5
  • 3 stars out of 5
  • 4 stars out of 5
  • 5 stars out of 5

0 out of 5 stars

Have your say